BlueRock Therapeutics launches with $225M Series A
December 13, 2016
Bayer and Versant Ventures have partnered to launch BlueRock Therapeutics, a stem cell therapy company with an initial focus on finding cures for heart and neurological conditions. The funding is one of the largest Series A financings ever for a biotech, according to the company. One of BlueRock’s first programs will be to regenerate heart muscle in patients who’ve suffered from heart attacks or chronic heart failure.